{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069183","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.874766+00:00","generated_at":"2026-05-21T23:37:53.530652+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xenon Q1 net loss $65.0M; X-TOLE2 topline data shifted to early 2026","bullets":["Net loss of $65.0M (vs $47.9M Q1 2024) on higher R&D spend of $61.2M; revenue $7.5M from Neurocrine milestone.","Cash and securities $691.1M (down from $754.4M Dec 2024); cash runway into 2027.","Phase 3 X-TOLE2 FOS study recruitment to complete in months; topline data now expected early 2026 (modest shift).","Phase 3 MDD (X-NOVA3) and bipolar depression studies on track to initiate mid-2025.","Phase 1 started for XEN1120 (Kv7); IND for XEN1701 (Nav1.7) expected Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069183","json":"https://secwatch.observer/filing/0000950170-25-069183.json","markdown":"https://secwatch.observer/filing/0000950170-25-069183.md","text":"https://secwatch.observer/filing/0000950170-25-069183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025069183/0000950170-25-069183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025069183/xene-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:37:53.530652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}